**Supplementary Table 1**. Clinical Manifestations – Signs and Symptoms

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Total** | **No cirrhosis** | **Cirrhosis** | **P-value** |
| **Variable** | N=2211 | N=2115 | N=96 |  |
| Fever, n (%) | 1430 (64.7) | 1385 (65.5) | 45 (46.9) | <.0011 |
| Cough | 1403 (63.5) | 1348 (63.7) | 55 (57.3) | 0.2 |
| Dyspnea | 1091 (49.2) | 1029 (48.6) | 62 (64.6) | 0.003 |
| Fatigue | 511 (23.5) | 473 (22.4) | 38 (39.6) | <.0001 |
| Sore throat | 538 (24.3) | 530 (25.1) | 8 (8.3) | <.0001 |
| Headache | 515 (23.3) | 494 (23.3) | 21 (21.8) | 0.9 |
| Rinorrea | 205 (9.3) | 201 (9.5) | 4 (4.2) | 0.08 |
| Nausea/Vomiting | 111 (5.0) | 106 (5.0) | 5 (5.2) | 0.9 |
| Diarrhea | 268 (12.1) | 259 (12.2) | 9 (9.4) | 0.4 |
| Myalgias-Arthralgias | 559 (25.3) | 541 (25.6) | 18 (18.7) | 0.1 |
| Anosmia | 213 (9.6) | 207 (9.8) | 6 (6.2) | 0.2 |
| Ageusia | 168 (7.6) | 162 (7.6) | 6 (6.2) | 0.6 |
| None | 97 (4.4) | 96 (4.5) | 1 (1.1) | 0.1 |

**Supplementary Table 2**. Treatments received by patients hospitalized for COVID-19

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Total** | **No cirrhosis** | **Cirrhosis** | **P-value** |
| **Treatment** | N=2211 | N=2115 | N=96 |  |
| Steroids, n (%) | 869 (39.3) | 831 (39.3) | 38 (39.6) | 0.9 |
| Antibiotics, n (%) | 1387 (62.7) | 1306 (61.7) | 81 (84.4) | <.0001 |
| Azythromicin, n (%) | 704 (31.8) | 664 (31.4) | 40 (41.7) | 0.03 |
| Low-weigh molecular heparin, n (%) | 1098 (49.6) | 1053 (49.8) | 45 (46.7) | 0.6 |
| Hydroxychloroquine, n (%) | 591 (26.7) | 571 (27.0) | 20 (20.8) | 0.2 |
| Lopinavir-ritonavir, n (%) | 161 (7.3) | 161 (7.6) | 0 (0) | 0.001 |
| Remdesvir, n (%) | 13 (0.3) | 13 (0.4) | 0 (0) | 0.5 |
| Oseltamivir, n (%) | 152 (6.9) | 145 (6.8) | 7 (7.3) | 0.8 |
| Plasmatic exchange, n (%) | 73 (3.3) | 71 (3.3) | 2 (2.1) | 0.5 |
| Tocilizumab, n (%) | 76 (3.4) | 75 (3.5) | 1 (1.0) | 0.2 |
| Ivermectine, n (%) | 121 (5.5) | 116 (5.5) | 5 (5.2) | 0.9 |